Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - IntelGenx Corp. (IGXT.OB-OTC: BB)

wpe11.jpg (7184 bytes)

“Our focus is on oral drug delivery. Our platform technologies include systems for controlled release and immediate release dosage forms.  Our controlled-release technology is based on layered tablets that consist of a non-erodible layer containing the active drug and one or more erodible cover layers. Upon contact of the tablet with the gastro-intestinal fluid, the cover layers erode at a pre-determined rate. This “controlled erosion” controls the release of an active drug from the...” - Horst G. Zerbe, Ph.D. (IGXT) (Interview published July 25, 2008)

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE |  COVER ARCHIVES  |  INDEX  |  CONTACT  |  FINANCIALS |  SERVICES  | HOME PAGE


CEOCFO-Members Login
Become A Member!



 

IntelGenx Technologies Corp. Shareholders Approved the Amendment of the 2006 Stock Option Plan


SAINT LAURENT, QUEBEC--(MARKET WIRE)--Feb 20, 2009 -- IntelGenx Technologies Corp. (CDNX:IGX.V - News)(OTC BB:IGXT.OB - News)("IntelGenx" or the "Company") confirms that the shareholders of the Company (the "Shareholders") approved the amendment of the 2006 Stock Option Plan (the "Plan") to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company's issued and outstanding shares as of July 28, 2008, at the Company's 2008 Annual General Meeting (the "Meeting") on September 8, 2008.
 

At the Meeting, the Shareholders also re-elected each of the directors of the Company and reappointed RSM Richter as the auditors of the Company for the year 2008.

The Company has granted to Mr. John A. Troup, a director of the Company, incentive stock options for the purchase of a total of 75,000 common shares of the Company at an exercise price of C$0.90 each until September 8, 2013. In addition, the Company has granted to Mr. Paul A. Simmons, the Chief Financial Officer of the Company, incentive stock options for the purchase of a total of 100,000 common shares of the Company at an exercise price of C$0.90 each until September 8, 2013. The options are being granted pursuant to the terms of the Plan.

ABOUT INTELGENX TECHNOLOGIES CORP.

IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company's research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation.



The OTCBB has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact:

     Contacts:
     IntelGenx Technologies Corp.
     Ingrid Zerbe
     Corporate Secretary
     (514) 331-7440 (ext. 202)
     (514) 331-0436 (FAX)
     Email: ingrid@IntelGenx.com
     Website: http://www.intelgenx.com


												

											

			

			
 

			


 

			



		

		
    


    

    
	

        

    

  







ceocfointerviews.com does not purchase or
make 

recommendation on stocks based on the interviews published.